Quantumup
Oct 12, 3:32 PM
UBS🏁
$NKTR and said: We initiate coverage of Nektar Therapeutics (NKTR) with a Neutral rating and a
$53 PT.
$REGN - SNY LLY GALD
$ABBV PFE INCY QTTB
Leerink🏁Nektar: Outperform-
$130/said—Rezpeg, a pot'ly first-in-class biologic that stimulates regulatory T-cells through the IL-2 receptor, has a multi-blockbuster opportunity—novel mechanism w/ pot'l application across many immunology indications—models combined gross peak sales of
$4B—sees current share levels as a favorable entry point.
Here's what UBS went on to say in its initiation report: https://x.com/Quantumup1/status/2109668440893964358?s=20
0 replies